Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
about
Preoperative chemotherapy for women with operable breast cancerPreoperative chemotherapy for women with operable breast cancerPredictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesPathologic Evaluation of Breast Cancer after Neoadjuvant TherapyFifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerHER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.Locally advanced noninflammatory breast cancer.Axillary lymph node involvement in stage III breast cancer: treatment implications.Breast cancer surgery--historical evolution, current status and future perspectives.Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective studyAnti-tumor effects of letrozole.Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapyNonsurgical approach in stage I and stage II breast cancer.Does neoadjuvant chemotherapy increase breast conservation in operable breast cancer: an Egyptian experienceStaging of breast cancer in the neoadjuvant setting.Breast-conserving therapy for mammary carcinoma: psychosocial aspects, indications and limitations.Breast conservation surgery: state of the art.Management of early breast cancer.Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility studyThe effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinomaThe Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-AnalysisAssesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.The Value of Combined Large Format Histopathology Technique to Assess the Surgically Removed Breast Tissue following Neoadjuvant Chemotherapy: A Single Institution Study of 40 Cases.Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancerPlasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapyEvaluation of surgical outcomes following oncoplastic breast surgery in early breast cancer and comparison with conventional breast conservation surgery.Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patientsPrimary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancerc-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
P2860
Q24245281-8AEAA4DE-5EA7-439D-A559-851BF1F6065DQ24246444-E5108DE2-0EA8-40E3-ABEA-DE4DA3A0B372Q24812541-A1FD5758-4C3C-49E1-8B86-D807647F822EQ26749261-65D28CA3-25D1-408E-8393-AD2FBB557B81Q28270514-8277F347-E65C-493E-9AC0-8075A7479BBEQ28364208-92725AA7-0E70-4D46-8125-E77325F7B538Q33275622-11B9955D-4B0C-4CCF-95E0-A37A9F7F8956Q33412047-78868119-8464-4DDE-925B-CA114F2290BBQ33547204-50DB2AFC-EA68-469D-B324-D56A1C6174DAQ33686269-3A24922C-C2BC-4850-80C5-3B365F7D30CBQ34231222-DFBD9001-F9BE-4688-BFE3-B29862FFDE2AQ34585753-B91112EA-9555-4F45-805A-C7F67E466EFAQ35004469-B28626A1-C7D6-481D-9E2D-ABC13FC3A107Q35194725-17ED3FCA-B862-4349-9BFB-004F216EA845Q35473058-354B2658-3FA7-4AA4-8BA1-86A20CB4D19BQ35572879-43574B9B-2CF5-4E4B-9BF8-80637721F798Q35638695-8BBA7D76-C931-4AB6-B10E-62B42C7F755AQ35659610-66D3F4AD-471D-4613-A782-5CD9F070C4A1Q35684401-938489A7-AAF0-42B3-BD7A-AE06C51B0EEBQ35821539-785D8BE3-F1E2-4E13-8C44-2D6D726763FAQ35978528-3BD9E238-97A4-44C1-BAE2-C2826DED84B8Q36079985-6BB45EE2-448C-4DA5-A30F-6593BCADD41DQ36126195-99F5449E-23DA-41D4-B85F-BC9F4B49E072Q36134796-6FD5D122-0DDB-4127-910C-C9B31E1DFC27Q36134870-663534FE-8C85-4F9A-9578-0DD87EB937C6Q36136174-6E4E0F84-43A8-44CE-AABF-B5AED68994F0Q36221963-208C8FF0-5CEC-483C-9646-6CC46A72E27FQ36355682-885E3EE1-AF96-4CFD-9DF8-14A0766578B1Q36423046-4AE12459-3650-4CAD-AB71-E7D67BE46259Q36430945-EF671128-0465-4D66-90B9-1D4B5857DFC8Q36431261-2B25E544-9976-4CA5-863D-C4F637AA67F1Q36431766-A70CF414-C5B3-4D68-95A2-F8FE95F78E85Q36492482-B7D30C2D-91BE-4E47-9AF2-13886744BE0EQ36613823-F708C4C7-0CC3-4560-B1D0-CF586FD29930Q36615222-F48BDBDC-FBAE-4D06-A047-3F77D9A7F520Q36615792-7D35DCFF-6A09-4E45-BD91-FF9CE9F37F32Q36617940-C5213F4E-4338-478B-AD48-C746F8351F8CQ36641854-3E0B1087-213B-485B-900A-413022D3F6B6Q36663561-91233B12-743F-4B82-8C13-0110A452447DQ36695226-3CAC3D66-E2CE-4B7C-8636-68DB0E117162
P2860
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
description
1990 nî lūn-bûn
@nan
1990 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Primary chemotherapy to avoid ...... of three centimeters or more.
@ast
Primary chemotherapy to avoid ...... of three centimeters or more.
@en
type
label
Primary chemotherapy to avoid ...... of three centimeters or more.
@ast
Primary chemotherapy to avoid ...... of three centimeters or more.
@en
prefLabel
Primary chemotherapy to avoid ...... of three centimeters or more.
@ast
Primary chemotherapy to avoid ...... of three centimeters or more.
@en
P2093
P356
P1476
Primary chemotherapy to avoid ...... of three centimeters or more.
@en
P2093
Bonadonna G
Brambilla C
Coopmans de Yoldi G
Veronesi U
P304
P356
10.1093/JNCI/82.19.1539
P407
P577
1990-10-01T00:00:00Z